Skip to main content
. 2020 Feb 26;25(5):1039. doi: 10.3390/molecules25051039

Figure 2.

Figure 2

Impact of heparin derivatives on platelet aggregation and secretion. (A,B) Representative traces showing platelet-tumor cell aggregation in response to MCF-7 cells. Platelets were preincubated for 30 min with (A) 100 µg/mL RO-heparin or (B) 100 µg/mL 2-O-desulfated heparin; (C) quantification of ATP release from MCF-7 cell stimulated platelets preincubated with 100 µg/mL RO-heparin or 100 µg/mL 2-O-desulfated heparin; (D,E) representative traces showing platelet-tumor cell aggregation in response to MCF-7 cells, platelets were preincubated with (D) 100 µg/mL hexasaccharide or (E) 100 µg/mL decasaccharide (n = 5); (F) quantification of ATP release from MCF-7 cell stimulated platelets preincubated with 100 µg/mL hexasaccharide or 100 µg/mL decasaccharide; (G) representative traces showing platelet-tumor cell aggregation in response to MCF-7 cells. Tumor cells were preincubated with 1 µg/1000 cells recombinant human P-selectin (n = 5); (H) representative traces showing platelet-tumor cell aggregation in response to MCF-7 cells. Platelets were preincubated with 100 µg/mL P-selectin inhibitor (n = 5); (I) quantification of ATP release from MCF-7 cell (preincubated with 1 µg recombinant human P-selectin/1000 cells in some experiments) stimulated platelets preincubated with 100 µg/mL P-selectin inhibitor. *** p < 0.001 indicated statistical significance.